Unipolar Depression | Access and Reimbursement | Major Depressive Disorder | US | 2019

Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies for the treatment of major depressive disorder (MDD). The MDD treatment armamentarium is becoming increasingly genericized, a trend that has improved patient access to antidepressants, as well as eased restrictions on off-label adjunctive use of atypical antipsychotics. At the same time, the expanding presence of generic drugs has given payers more leverage to control drug treatment costs in MDD. Understanding the current and expected influence of clinical metrics and value-for-dollar on market access and medical practice is key for developers of new therapies for MDD.

QUESTIONS ANSWERED

• In this mature and highly generic treatment landscape, what actions can marketers of MDD therapies taketo gain market access and thus ensure uptake?
• How do payer policies affect the prescribing of branded oral atypical antipsychotics (e.g., Lundbeck/Otsuka Pharmaceutical’s Rexulti, Allergan’s Vraylar) and antidepressants (e.g., Lundbeck/Takeda’s Trintellix, Allergan’s Viibryd) in this genericized market?
• To which of their MDD patients do physicians anticipate prescribing the emerging therapies esketamine (Janssen), gepirone ER (Fabre-Kramer), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Markets covered: United States

Primary research: Survey of 50 U.S. primary care physicians, 50 U.S. psychiatrists, and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs) fielded in January 2019.

Key companies: Allergan, Eli Lilly, Fabre-Kramer Pharmaceuticals, Janssen, Lundbeck, Otsuka, Sunovion, Takeda,

Key drugs: Duloxetine (Cymbalta, generics), Latuda, Rexulti, Trintellix, Viibryd, Vraylar, esketamine, gepirone ER, rapastinel

Content highlights:

• Reimbursement and contracting
• Access and prescribing
• Special topics
• Opportunities and challenges for emerging therapies